Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication.

摘要: Summary Background and Aim To test whether the chronic users of celecoxib, a selective cyclo-oxygenase-2 inhibitor, had less Helicobacter pylori-related intestinal metaplasia or if such users’ could be prone to disappear after H. pylori eradication. Methods The study enrolled 150 celecoxib 216 non-users who underwent pan-endoscopy detect infection its related metaplasia. One hundred three pylori-infected patients with (43 60 non-users) received anti-H. therapy completed 12-month follow-up survey regression by mean score. Results There were no differences in prevalence between controls (P > 0.05). On 12th month follow-up, lower score (1.2 vs. 1.8, P < 0.005) higher rate (42% 20%, P = 0.027) than non-users. Conclusions With infection, still showed limited effects decrease Nevertheless, should promising assist eradication for control gastric cancer risk.